Capricor Q2 Loss Widens to $40.7M; Cash Drops to $237.9M Amid FDA Review Uncertainty

summarizeSummary

Capricor reported a wider Q2 loss of $40.7M and a cash decline to $237.9M, while withdrawing its injunction against NS Pharma and disclosing an FDA Form 483 observation, all ahead of the August 22 PDUFA decision.

check_boxKey Events · Earnings and Guidance · CAPR

• Q2 Loss Widens 57%

  Net loss of $40.7 million ($0.70/share) versus $25.9 million ($0.57/share) in Q2 2025, driven by a 55% increase in operating expenses to $42.9 million.

• Cash Burn Accelerates

  Cash, equivalents, and marketable securities fell to $237.9 million from $318.1 million at year-end 2025, a decline of $80.2 million in six months.

• NS Pharma Injunction Withdrawn

  Capricor withdrew its motion for preliminary injunction against NS Pharma, moving the contractual dispute to arbitration expected to begin this fall.

• FDA Form 483 Observation

  An FDA Bioresearch Monitoring inspection in July 2026 resulted in one Form 483 observation; the company has submitted responses and awaits feedback.

auto_awesomeAnalysis · CAPR · Life Sciences

Capricor's second-quarter results show a sharply widening loss and accelerating cash burn as the company prepares for a potential FDA decision on Deramiocel. The net loss of $40.7 million is 57% higher than the same quarter last year, driven by a 55% jump in operating expenses. Cash fell by $80 million in six months to $237.9 million, though management says this is enough for at least twelve months. The filing also reveals the company withdrew its preliminary injunction motion against NS Pharma, moving that dispute to arbitration, and disclosed a Form 483 observation from an FDA manufacturing inspection. These updates come just nine days before the August 22 PDUFA date, following a negative advisory committee vote and a securities fraud lawsuit.